Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-398 + Osimertinib in EGFR-mutant NSCLC
NCT06032936Phase 1Terminated
- Sponsor
- LianBio
- Start
- Jul 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986466 in non-small cell lung cancer (NSCLC), sponsored by LianBio. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 1 more. Started Jul 2023; status: terminated.
02
Drugs
BMS-986466
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06032936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06032936.